LGD-4033
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
High-potency lean-mass and strength SARM with secondary bone/rehab interest; best read as an oral anabolic shortcut with full endocrine consequences, not a mild supplement.
At community doses, LGD-4033 can behave like a high-tax endocrine intervention: expect HPG suppression, lipid strain, water/gyno-prone shifts, anti-doping risk, and real recovery planning.
High-potency lean-mass and strength SARM with secondary bone/rehab interest; best read as an oral anabolic shortcut with full endocrine consequences, not a mild supplement.
High suppression tax: community bloodwork at 10mg/day shows LH/FSH can become undetectable and total testosterone can fall below 100 ng/dL by weeks 3-4. HDL reduction, water retention, lethargy, gyno-prone E/T ratio shifts, failed recovery/PCT, anti-doping detection, and female virilization are the practical red flags.
LGD-4033 is the mass-gain SARM people reach for when Ostarine feels too soft: 5-8 lb lean-mass gains over 8 weeks at 10mg/day are the recurring community benchmark when food and training are aligned. The same dose range also turns it into a high-tax endocrine intervention, so the real value case is narrow: experienced users with labs, recovery planning, and a reason to avoid or delay injectable AAS.
High for lean mass and gym performance, modest for fat loss, and conditional for recovery/reconditioning. The clinical human data is low-dose and short (0.1-1.0mg/day for 21 days); the stronger 5-20mg, 8-12 week claims mostly come from community logs and should be weighted as practical signal, not controlled evidence.
Intro
LGD-4033, also known as Ligandrol, is a nonsteroidal oral selective androgen receptor modulator (SARM) developed by Ligand Pharmaceuticals in San Diego and later licensed to Viking Therapeutics as VK5211.
Synthesized to address concerns about testosterone's prostate effects, LGD-4033 binds the androgen receptor with high affinity and selectivity — producing muscle and bone anabolism while theoretically sparing the prostate at clinical doses.
The key pharmacological claim: preclinical data from Vajda et al. (2009) established a 500:1 anabolic-to-androgenic ratio for LGD-4033 relative to testosterone, based on levator ani muscle stimulation versus ventral prostate stimulation in orchidectomized male rats. At community doses (5-20mg/day), this selectivity window narrows and eventually closes — the compound behaves increasingly like a low-dose androgen as dose rises.
The only published human Phase I trial is Basaria et al. (2013), a placebo-controlled study of 76 healthy men randomized to 0.1, 0.3, or 1.0 mg/day for 21 days. Lean body mass increased dose-dependently (p for trend = 0.04 at 1.0 mg), PSA did not change, and all hormone changes reversed within 5 weeks of stopping. No drug-related serious adverse events occurred. This trial tested doses 5-20x lower than what the community uses for 21 days versus 8-12 weeks — extrapolating its safety data to community protocols is not supported by evidence.
Viking Therapeutics completed a Phase II trial of VK5211 in hip fracture patients showing lean mass and stair-climbing power improvements, but has not advanced to Phase III. LGD-4033 has been prohibited by WADA since 2010, generating 62 adverse analytical findings in 2019 alone — making it one of the most detected performance-enhancing compounds in anti-doping.
Community adoption began in 2013 through early performance-forum cycle logs. The protocol framework established in those early logs — 8-12 week cycles, SERM-based PCT — has remained stable for over a decade. LGD-4033 is now the default 'first enhanced compound' before AAS for a substantial portion of the performance community, and a common add-on for TRT patients seeking lean mass without additional testosterone.
Observed Effects
Lean body mass: The most consistent finding across clinical and community data. Basaria et al.
(2013) showed dose-dependent lean mass increase at 1.0 mg/day for 21 days. Community logs at 10mg/day for 8 weeks report 5-8 lbs of lean mass gain in a calorie surplus, with strength logs showing bench press +20 lbs and squat +35 lbs over the same period. Visible body composition changes typically appear by weeks 5-6.
Strength: Basaria et al. found no statistically significant strength improvement (p = 0.203 for leg press) over 21 days, which is too short for meaningful neuromuscular adaptation. Community logs consistently report strength gains starting weeks 2-3, with a marked acceleration at weeks 3-4 described as 'extraordinary pump.' Specific logs: bench +5 lbs by week 2 at 2.5mg/day, squat PR at day 14 at the same dose; bench +20 lbs, squat +35 lbs at 10mg/day over 8 weeks. The week 1-2 strength improvement reflects non-genomic AR signaling (rapid, CNS-mediated); weeks 3-8 reflect genuine muscle protein synthesis.
Bone mineral density: Established in preclinical OVX female rat data (Vajda 2009) — 12 weeks of LGD-4033 improved DEXA, bone histomorphometry, and biomechanical strength in a model of established osteopenia. VK5211 Phase II data in hip fracture patients supports translation to humans. Community users with orthopedic injury contexts report faster recovery and reduced training pain — consistent with bone/connective tissue support.
Fat mass: Did not change significantly in Basaria et al. (p for trend = 0.261). Community logs report no meaningful fat loss at 10mg in a surplus, but recomp effects (fat loss while gaining muscle) at maintenance or mild deficit. Scale weight is an unreliable endpoint given 2-5 lbs water retention during active use.
Water retention: Consistent across all community logs — 2-5 lbs of water during active cycle, resolving within 2 weeks of stopping. Likely reflects mineralocorticoid-adjacent activity or increased glycogen storage (each gram glycogen holds ~3g water). Visible in face and limbs. Makes strength and tape measurements more reliable than scale weight.
Pump and fullness: Day 1 pump improvements reported even at 2.5mg. This is non-genomic AR signaling — rapid and not dependent on weeks of accumulation. Subjectively described as distinctly different from training without SARM support.
Field Reports
The 'gateway' experience is the most consistent narrative: users arrive from Ostarine or Cardarine describing LGD-4033 as 'the first that actually felt like something was happening.' Day 1 pump improvements are routinely reported even at 2.5mg. Weeks 3-4 bring the dramatic strength acceleration that drives most positive reviews — multiple logs describe this phase as transformative.
The cautionary experience is equally consistent: an 8mg/day, 8-week no-PCT log described poor gains relative to the suppression cost. Lethargy, worsening puffy nipples, water retention, and appetite suppression without adequate support or recovery structure produced a net-negative outcome. This is the outcome when the suppression cost isn't managed.
A detailed community log documents the experience in high granularity: 28-year-old, 8 years lifting, 2.5mg/day to avoid PCT, 500 kcal surplus. Day 1: immediate pump and energy. Days 4-10: lethargy outside the gym. Week 2: bench +5, deadlift +5, squat PR at day 14. Weeks 3-4: dramatic strength and pump increase. The pattern — flat first two weeks, then sharp acceleration at weeks 3-4 — is the most reproducible temporal profile across all logs.
Common mistakes the community has identified over 12 years of data: - Running without bloodwork and discovering mid-cycle how suppressed you are - Skipping PCT because 'SARMs don't suppress that much' (they do) - Setting unrealistic expectations based on scale weight (2-5 lbs is water) - Starting at too low a dose (5mg) for too long without results, then abandoning the compound - Extending cycles beyond 12 weeks without additional reasoning - Using LGD-4033 at 18-22 years old before the HPTA has reached full adult function
A recent log from a 23-year-old following standard Clomid PCT shows that modern users are working from the same 2013-era protocol — reflecting both the durability of the framework and the limited evolution of harm reduction education over 12 years.
Community Consensus
Community consensus is unusually stable: LGD-4033 is the SARM people choose when the goal is visible lean-mass gain rather than subtle recomp.
It is usually placed above Ostarine/Cardarine in anabolic feel, below traditional AAS in overall ceiling, and close enough to steroid territory that experienced users talk about recovery planning before the first dose rather than after side effects appear.
Two use cases dominate. Natural users run LGD-4033 as a first enhanced compound and carry the full suppression problem: baseline labs, mid-cycle LH/FSH/testosterone, a SERM or enclomiphene PCT plan, and enough off-time to prove recovery. TRT users use it as a lean-mass add-on where the testosterone-crash problem is less central, but lipid changes, androgenic effects, sourcing quality, and anti-doping risk still remain.
The positive consensus is not timid: users repeatedly describe stronger pumps, faster progression, and 5-8 lb lean-mass outcomes when diet and training support the cycle. The negative consensus is just as clear: bad LGD cycles usually fail because the user underestimates shutdown, mistakes water for tissue, skips labs, or treats PCT as optional. The practical stance is therefore bullish but bounded, not beginner-friendly.
Alternate forms exist, including injectable LGD-4033 preparations marketed as a way to bypass first-pass metabolism or change onset speed. The article evidence does not establish that injectable forms improve outcomes or safety enough to change the default oral-cycle framework, so this belongs in the experimental/source-fragility lane rather than the core recommendation lane.
Female use appears as a small harm-reduction subculture, usually 1-2.5mg/day for short recomp attempts. That does not make LGD-4033 a recommended female anabolic: menstrual disruption can appear at low doses, virilization risk rises quickly, and any voice, clitoral, hairline, acne, or cycle-disruption signal should be treated as a stop condition rather than normal cycle noise.
Risks & Monitoring
HPG axis suppression (universal at community doses): At 10mg/day, community bloodwork documents LH and FSH dropping to undetectable and total testosterone falling below 100 ng/dL within 4 weeks.
This is secondary hypogonadism — the hypothalamus and pituitary shut down in response to LGD-4033's AR activation. The Basaria Phase I trial showed suppression beginning even at 0.1 mg/day (SHBG and total testosterone), with full FSH/free testosterone suppression at 1.0 mg/day. At community doses (10-20x higher), suppression is complete and rapid. Suppression severity shows 3-7x inter-individual variability — some users at 10mg/day retain testosterone above 200 ng/dL; others crash to <50 ng/dL. Only mid-cycle bloodwork (weeks 3-4) can determine individual response.
PCT failure and permanent hypogonadism: The strongest corpus warning is that SARM suppression and imperfect PCT recovery can leave some men dependent on TRT. Repeated cycles without full HPTA recovery, or individual responders who do not recover naturally, face permanent reliance on TRT. This is the defining risk that distinguishes LGD-4033 from peptides.
Lethargy: Most commonly reported non-hormonal side effect. Appears days 4-14, typically resolves mid-cycle. Expressed primarily outside the gym — normal or supranormal training energy while fatigued at rest. Mechanism: testosterone suppression with LGD-4033 not fully compensating for the androgenic effect on CNS energy.
Water retention: 2-5 lbs during active use, resolving within 2 weeks post-cycle. Not health-threatening but confounds scale-based progress tracking.
Estrogen dominance / gynecomastia risk: LGD-4033 does not aromatize directly. However, as total testosterone drops while estradiol remains relatively stable, the estrogen-to-testosterone ratio shifts toward estrogen dominance. Users with pre-existing gynecomastia sensitivity (as in a negative community log where puffy nipples worsened) are at elevated risk. Running an AI is generally not indicated (LGD doesn't aromatize) but raloxifene or tamoxifen can address gyno symptoms if they emerge.
HDL cholesterol reduction: Dose-dependent, documented in Basaria et al. Normalized within 5 weeks of stopping. At community doses over 8-12 weeks, the reduction may be more pronounced than the clinical trial data suggests.
Appetite suppression: Reported by some users, potentially counterproductive on a bulking cycle. Mechanism unclear.
Headaches: First 1-2 weeks, typically resolving. Possibly hemodynamic changes from SHBG/testosterone flux.
Virilization in women: At doses above 5mg, voice changes and clitoral enlargement reported. Menstrual disruption documented even at low doses. Women use 1-2.5mg; 5mg maximum.
PSA / Liver / QT: No significant change in PSA, AST, ALT, or QT interval in Basaria et al. at doses up to 1.0 mg/day for 21 days. No long-term liver data at community doses.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Baseline hormone values are essential for interpreting mid-cycle and post-cycle bloodwork. Without a pre-cycle baseline, it is impossible to determine the degree of suppression or confirm PCT recovery. LH/FSH values of 0 mid-cycle only mean something if you knew they were normal at baseline.
SHBG suppression begins at the lowest clinical doses (0.1mg in Basaria 2013). Baseline establishes normal range; mid-cycle SHBG drop confirms LGD-4033 is active. SHBG also affects free testosterone calculation and determines how much total testosterone is bioavailable.
HDL reduces dose-dependently during LGD-4033 use (documented in Phase I). Baseline establishes pre-cycle cardiovascular risk profile; mid-cycle or end-of-cycle values confirm the reduction magnitude. At community doses over 8-12 weeks, HDL suppression may be clinically significant.
Hemoglobin did not change significantly in the Phase I trial, but hematocrit monitoring is standard for any compound affecting androgen receptor signaling. Establishes baseline before any erythropoietic effects could manifest at higher doses or longer cycles.
AST and ALT did not change significantly in the Phase I trial. However, at community doses (10-20x the clinical trial maximum) over 8-12 weeks, baseline liver function is a prudent reference point. LGD-4033 is oral but not a 17-alpha-alkylated compound — hepatotoxicity risk is considered low but unverified at community doses.
Mid-cycle bloodwork (weeks 3-4) is the most important safety check. This is when suppression is fully established. LH/FSH at undetectable + total testosterone below 100 ng/dL confirms expected suppression. Individual response varies 3-7x — only bloodwork determines whether you are a severe or mild suppressor. Users on TRT can skip this; natural users should not.
Post-cycle bloodwork (4-6 weeks after last dose, during or after PCT) confirms HPTA recovery. Target: LH and FSH returning toward baseline, total testosterone recovering. In the Phase I trial, recovery was confirmed within 5 weeks at 1.0mg/21-day dose — community doses and longer cycles may require longer recovery periods. Lipids should also be checked to confirm HDL recovery.
LGD-4033 does not aromatize, but as testosterone drops and estradiol remains stable, the E/T ratio shifts toward estrogen dominance. In users with pre-existing gyno sensitivity, this ratio shift produces puffy nipple or gyno symptoms. Estradiol measurement mid-cycle guides the decision to use tamoxifen or raloxifene if symptoms emerge.
PSA did not change in the Phase I trial (0.1-1.0mg for 21 days). At community doses, the tissue selectivity window narrows — a baseline PSA is reasonable for users over 40 or those planning extended cycles. Not essential for young users on standard 8-week cycles.
Avoid With
Do not combine LGD-4033 with the following. Sorted highest-severity first.
Why:All SARMs suppress the HPG axis via AR agonism in the hypothalamus/pituitary. Stacking multiple suppressive SARMs compounds the hormonal shutdown without proportional anabolic benefit. Recovery becomes significantly more difficult and PCT failure risk increases.
What to do:Advanced users who run SARM stacks accept this risk deliberately. Not recommended for anyone without confirmed recovery from prior solo LGD cycles.
Why:Stacking LGD-4033 with supraphysiological testosterone produces additive androgen receptor saturation and combined suppression. The marginal anabolic benefit from adding LGD-4033 to an already androgenic testosterone dose is unclear; the additional lipid and cardiovascular burden is additive.
What to do:TRT doses (100-200mg/week) as a testosterone base with LGD-4033 are a well-established community practice. The concern is with blast-level testosterone doses (400mg+) where adding LGD-4033 represents unknown compound interaction at supraphysiological AR stimulation.
Why:LGD-4033 is not a 17-alpha-alkylated compound and carries low direct hepatotoxicity. However, stacking with known hepatotoxic oral steroids adds liver stress without clear additional benefit from LGD-4033. ALT/AST monitoring becomes critical if this combination is used.
What to do:The community practice of 'SARM kickstart + testosterone' avoids this issue. The problem arises when LGD-4033 is used alongside oral AAS rather than injectable testosterone.
Why:LGD-4033 is not converted by 5-alpha reductase (it is not a DHT precursor), so 5AR inhibitors do not reduce LGD-4033's androgenic effects. Unlike testosterone, LGD-4033's side effects cannot be mitigated by finasteride. Users expecting this mechanism to provide prostate protection are mistaken.
What to do:If already on finasteride for hair loss or BPH, this does not reduce LGD-4033's androgenic burden. The compound's androgenic effects at high doses are direct, not DHT-mediated.
Protocols By Goal
Lean bulking: Common reports use about 10 mg/day for 8 weeks with a caloric surplus and planned recovery support. Outcomes are usually framed as several pounds of lean mass plus transient water weight, not pure permanent tissue.
Body recomposition: Reports use 5-10 mg/day for 8-10 weeks around maintenance calories or a small deficit, usually in users already lean enough for visual changes to show.
Cutting / muscle preservation: Lower-dose reports around 3-5 mg/day appear during deficits, but suppression is still possible and recovery planning remains relevant.
TRT add-on: Some TRT users add 2-5 mg/day to prescribed testosterone. This removes the solo-cycle testosterone-crash problem but not HDL reduction, androgenic effects, source quality, or anti-doping risk.
Injury recovery / reconditioning: 5 mg/day for 8-12 weeks appears in recovery-oriented reports, but underlying injury stability matters and the clinical evidence does not make LGD a low-risk rehab peptide.
Steroid cycle kick-start: Some enhanced users use 10 mg/day early in long-ester testosterone cycles, but that turns the cycle into a more complex suppressive-and-lipid-risk stack.
Female harm-reduction boundary: LGD-4033 is not recommended as a female anabolic protocol. If a woman has already chosen exposure, community harm-reduction reports cluster around 1-2.5 mg/day for short periods, with pregnancy possibility, menstrual disruption, voice change, clitoral change, hairline recession, or rapid acne/libido changes treated as stop conditions. Prefer non-androgenic longevity, injury-recovery, or body-composition strategies before considering a suppressive SARM.
Dosing Details
Observed community dose bands - First-cycle reports: 5-10 mg/day for about 8 weeks - Intermediate reports: 10-15 mg/day for 8-10 weeks - Advanced reports: 15-20 mg/day for 8-12 weeks - Women: not recommended; harm-reduction-only reports cluster around 1-2.5 mg/day for 6-8 weeks, with 5 mg as a community ceiling rather than a target - TRT add-on reports: 2-5 mg/day, with the testosterone base preventing the solo-cycle crash but not removing lipid, androgenic, or anti-doping risk
Functional categories in community framing: lower-dose cutting/preservation, mid-range lean bulk, and higher-dose mass-building use. Suppression is dose-dependent but not absent at low doses.
Administration: Oral once daily is the default reported route. Sublingual claims exist but have no clear pharmacokinetic advantage in the article evidence.
Cycle duration: 8 weeks is the common first-cycle frame; 10-12 weeks appears in experienced-user reports. Longer use is uncommon and associated with harder HPTA recovery.
Suppression mitigation and PCT: Some advanced users use enclomiphene or HCG during exposure to preserve LH/FSH signaling, and post-cycle reports commonly use tamoxifen, clomiphene, or enclomiphene. These are observed recovery practices, not a blanket instruction; bloodwork determines whether recovery is actually happening.
Injectable form: Injectable LGD-4033 preparations exist in community markets, but the article evidence does not show a clear safety or efficacy advantage over oral LGD-4033.
Stacks & Alternatives
The most commonly recommended addition to a first LGD-4033 cycle. MK-677 stimulates GH and IGF-1 secretion via ghrelin receptor agonism — adds a GH secretagogue axis to LGD's AR-driven anabolism without additional HPG suppression. Synergistic for lean mass and recovery. No additional bloodwork requirements beyond the standard LGD monitoring.
High-potency SARM stack for experienced users. Both SARMs suppress HPG axis — stacking compounds the suppression. Used by advanced community members targeting maximum anabolic stimulus. Expect complete hormonal shutdown; PCT complexity increases. Not recommended for first SARM cycles.
PPARδ agonist (not a SARM). Stacked with LGD-4033 for the recomp context: Cardarine improves fat oxidation and endurance, LGD provides the anabolic stimulus. The combination allows higher training volume during a caloric deficit. Note: Cardarine was abandoned in clinical development due to tumorigenesis in animal models at high doses.
The safest approach to running LGD-4033: a testosterone base prevents the endogenous testosterone crash that causes lethargy, libido loss, and muscle loss during LGD-4033-induced suppression. Converts a high-risk solo SARM cycle into a lower-risk (though still suppressive) testosterone + SARM stack. Requires injection.
Running 12.5-25mg Enclomiphene from day 1 of the LGD-4033 cycle to maintain LH and FSH signaling and prevent testicular atrophy. An evolving community practice — requires bloodwork confirmation that LH/FSH are maintained. If it works, eliminates the need for post-cycle PCT.
Often stacked to protect connective tissue during the accelerated strength gains from LGD-4033. Tendons and ligaments can lag behind the rapid strength improvements, increasing injury risk. BPC-157 supports tissue healing and collagen synthesis, potentially reducing this liability.
Alternatives
Stack Cost
High tax: LGD-4033 is cheap and simple to dose, but the useful mass-gain range creates a full suppressive SARM lane with hormone labs, lipid monitoring, PCT/off-ramp planning, identity verification, anti-doping risk, and poor beginner margin.
The article frames HPG shutdown as the central cost: LH/FSH can become undetectable and total testosterone can fall below 100 ng/dL by weeks 3-4 in severe 10mg/day community responders. PCT failure and long-term TRT dependence remain the defining downside, even if not every user crashes equally.
The article notes dose-dependent HDL reduction in Basaria et al. and recommends lipid monitoring. Liver and PSA signals were clean only at 0.1-1.0 mg/day for 21 days, far below 5-20 mg community protocols.
recommendedPanels requires baseline, mid-cycle, and post-cycle hormone checks plus SHBG, lipids, CBC, CMP, and estradiol when symptoms warrant it. The article says users who will not run bloodwork face unacceptable risk.
For men, LH/FSH shutdown creates fertility and testicular-function consequences. For women, the tax is higher: menstrual disruption, virilization risk, and pregnancy contraindication make LGD-4033 harm-reduction-only rather than a normal protocol option.
stackingConflicts warns against stacking suppressive SARMs, supraphysiologic testosterone, and hepatotoxic oral AAS because hormonal shutdown, lipid burden, and recovery complexity compound.
- ·Counts as a full suppressive SARM lane for natural users; do not add another suppressive SARM unless complete shutdown and harder recovery are explicitly accepted.
- ·Do not treat a TRT base as removing all tax; it removes the testosterone-crash problem but leaves HDL, BP-adjacent cardiovascular context, androgenic side effects, and sourcing risk.
- ·Any solo cycle requires a recovery lane: planned SERM or enclomiphene PCT, post-cycle bloodwork, and enough off-time to confirm HPTA return before the next cycle.
- ·Avoid using LGD-4033 as a first enhanced compound if baseline labs, mid-cycle labs, and post-cycle labs are not available.
- ·Do not combine with hepatotoxic oral AAS without escalating liver and lipid monitoring beyond the standard LGD protocol.
- ·Baseline total testosterone, free testosterone, LH, FSH, SHBG, lipid panel, CBC, and CMP before starting.
- ·Mid-cycle hormone and lipid check at weeks 3-4 because suppression is often fully established by then.
- ·Post-cycle recovery labs 4-6 weeks after the last dose or after PCT to confirm LH/FSH and testosterone recovery.
- ·A defined PCT plan using tamoxifen, clomiphene, or enclomiphene for natural users.
- ·Estradiol-sensitive testing and symptom tracking if gyno, mood, libido, or estrogen-dominance signs appear.
The article explicitly rates LGD-4033 advanced because the harm profile is dominated by complete HPG suppression, PCT failure risk, lipid changes, and high-dose extrapolation beyond the clinical trial range.
- ·No willingness to run mid-cycle or post-cycle bloodwork.
- ·Under age 25 or still establishing adult HPTA baseline.
- ·Trying to preserve fertility without a clear plan.
- ·Prior poor recovery from SARMs, AAS, or unexplained low testosterone.
- ·Female user seeking an anabolic protocol rather than harm-reduction guidance after already choosing exposure.
Stopping the oral compound is simple, but the biological off-ramp is hard because testosterone, LH, FSH, SHBG, lipids, libido, mood, and water retention can all lag behind discontinuation. The article names PCT failure as a real outcome.
- ·Low testosterone symptoms after cessation if LH/FSH do not restart promptly.
- ·Need for tamoxifen, clomiphene, or enclomiphene PCT and follow-up labs.
- ·Persistent low libido or lethargy during recovery.
- ·HDL recovery lag after longer or higher-dose cycles.
- ·Water-weight changes masking true tissue changes after stopping.
Run baseline and mid-cycle labs, use a planned PCT or TRT-base strategy, and stop extending the cycle if suppression is severe.
Treat lipid panels as required, keep cycle length bounded, and avoid hepatotoxic or lipid-hostile oral stacks.
Do not use an aromatase-inhibitor reflexively; check sensitive estradiol and use tamoxifen or raloxifene only if symptoms warrant it.
Stop immediately and monitor FSH, LH, estradiol, and total testosterone at weeks 4 and 8; seek endocrinology review if cycles do not normalize.
The article's central risk is worsening or failing to recover HPG-axis function; starting from a compromised baseline removes the margin.
The article says bloodwork determines individual suppression severity and recovery; without it the user cannot distinguish a normal cycle from a dangerous one.
LGD does not aromatize, but the article explains that testosterone collapse can shift the estrogen-to-testosterone ratio and worsen puffy nipples or gyno symptoms.
LGD-4033 is not recommended as a female anabolic. The article rates virilization risk high, pregnancy contraindicated, and menstrual disruption plausible even at low doses.
Practical Setup
Quality and anti-doping: LGD-4033 purity and identity vary in unregulated products. Batch-specific third-party testing is a quality-control minimum in community harm reduction, especially for tested athletes.
Anti-doping risk is meaningful because both intentional use and contaminated products have produced adverse analytical findings.
Detection window: Parent compound can be detectable in urine for weeks at supplement levels, and metabolite ratios may help estimate timing. Any athlete in a WADA-tested sport faces meaningful disqualification risk.
Storage: Store product according to its actual formulation. Liquid or capsule forms are not interchangeable if concentration or identity is unclear.
Drug interactions: Published interaction data are limited. Clinicians managing TRT patients who self-administer LGD-4033 should know that HDL reduction, SHBG changes, and testosterone suppression can distort otherwise unexplained bloodwork.
Legal status and disclosure: LGD-4033 is an unapproved research chemical rather than a regulated medicine. It is not appropriate to sell for human consumption in many jurisdictions. Disclose use to treating clinicians so abnormal SHBG, lipid, LH/FSH, or testosterone results are interpreted correctly.
Mechanism Deep Dive
Selective Androgen Receptor Binding LGD-4033 is a nonsteroidal SARM — a pyrrolidinyl-trifluoromethyl benzonitrile derivative — that binds the androgen receptor (AR) with high affinity and selectivity.
Competitive binding assays using recombinant baculovirus-expressed AR established Ki values demonstrating high affinity comparable to DHT, with selectivity confirmed against related steroid receptors (estrogen receptor, progesterone receptor, glucocorticoid receptor). The compound functions as a full AR agonist in transcriptional activity assays — LGD-4033-bound AR activates AR-responsive promoter constructs in CV1 cells transfected with human AR.
Tissue Selectivity The central pharmacological claim: in preclinical orchidectomized male rat models, LGD-4033 restored levator ani (skeletal muscle) mass to near-intact levels at doses that produced significantly less ventral prostate stimulation than testosterone. The tissue selectivity ratio was quantified at approximately 500:1 (muscle:prostate) relative to testosterone (Vajda et al., 2009). The mechanism driving this selectivity is not fully established — it likely involves differential cofactor recruitment by the LGD-4033-AR complex in muscle versus prostate tissue, producing different transcriptional outcomes from the same receptor in different cell types.
Selectivity Ceiling at High Doses Critically, tissue selectivity is not dose-independent. Community synthesis of clinical data and user bloodwork makes the practical point clearly: selectivity is lost at higher doses — prostate stimulation approaches testosterone-like levels as dose increases beyond the therapeutic window. This explains why the PSA findings from the Phase I trial (1.0 mg/day for 21 days) may not predict prostate safety at 10-20mg/day for 8-12 weeks.
SHBG Binding LGD-4033 and other SARMs bind SHBG in addition to the androgen receptor. This SHBG binding is documented through clinical bloodwork analysis — SHBG suppression begins at 0.1 mg/day in the Basaria trial, earlier and at lower doses than FSH/LH suppression. The SHBG interaction affects free testosterone calculation (free T = total T / SHBG-bound fraction), and the SHBG drop transiently increases free androgen availability before the HPG axis suppression reduces total testosterone.
HPG Axis Suppression AR agonism in hypothalamic neurons reduces GnRH pulse frequency and amplitude. This reduces pituitary LH and FSH secretion, which reduces testicular testosterone synthesis (Leydig cell steroidogenesis). The result is secondary hypogonadism — the testes are functionally intact but receive no stimulatory signal. At community doses (10-20mg), this cascade produces complete HPG shutdown within 3-4 weeks: LH undetectable, FSH undetectable, testosterone below 100 ng/dL.
Non-Genomic Rapid Effects The cell surface AR (distinct from the nuclear AR, not bound to heat shock proteins) mediates rapid responses — pump, mental acuity, and strength improvements within hours of first dose. This is non-genomic signaling: the surface AR activates ion channels, kinase cascades, and second messengers without requiring gene transcription. The pump and energy users feel on day 1 of LGD-4033 use are surface AR-mediated. Hypertrophy requires the nuclear pathway — weeks of sustained AR activation driving protein synthesis gene expression.
Training-Induced AR Upregulation Resistance training increases androgen receptor density and content in skeletal muscle — by increasing β-catenin-androgen receptor complexes and activating AMPK pathways. This means experienced trainees have more AR sites for LGD-4033 to activate, providing mechanistic grounding for the community observation that trained athletes respond better than beginners at equivalent doses.
Bone Mechanism In ovariectomized female rats with established osteopenia, 12 weeks of LGD-4033 improved femur DEXA, bone histomorphometry, and biomechanical strength (bending load to fracture). The bone effect likely mirrors the AR-mediated pathway active in osteoblasts — androgens stimulate bone formation while reducing resorption through AR-positive osteoblast activation and indirect effects on osteoclast regulation.
Metabolism and Detection LGD-4033 undergoes hepatic oxidative metabolism, producing 15 phase I metabolites in human urine (Fragkaki et al., 2018). The dihydroxylated M5 metabolite isomers are the preferred anti-doping targets. The parent compound and its M1 epimer are detectable at 8 pg/mL LOD by LC-HRMS. At micro-doses as low as 1 µg, parent compound is detectable; the M1/LGD-4033 ratio shifts over time and can estimate time of administration. Detection window at supplement doses extends to ~21 days post-use.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Basaria et al. (2013) tested LGD-4033 at 0.1, 0.3, and 1.0 mg/day for 21 days, showing dose-dependent lean body mass increase at 1.0 mg/day, no PSA/AST/ALT/QT signal, and hormone recovery within 5 weeks.
The article correctly warns that this does not establish safety for community protocols of 5-20 mg/day for 8-12 weeks.
Community logs at 10 mg/day for 8 weeks report 5-8 lb lean mass gain and strength gains such as bench +20 lb and squat +35 lb.
Useful real-world signal for likely effect size at bodybuilding doses, but uncontrolled diet/training, water retention, and survivorship bias mean it should not be treated as clinical efficacy evidence.
At 10 mg/day, community bloodwork documents LH and FSH dropping to undetectable and total testosterone falling below 100 ng/dL within 4 weeks.
The article notes 3-7x inter-individual variability, so this should be read as a severe plausible response rather than a guaranteed exact value for every user.
Preclinical data from Vajda et al. established an approximately 500:1 anabolic-to-androgenic ratio relative to testosterone in orchidectomized male rats.
This supports the tissue-selectivity mechanism but should not be generalized to high-dose community human cycles where the evidence indicates selectivity narrows.
In ovariectomized female rats with established osteopenia, 12 weeks of LGD-4033 improved DEXA, bone histomorphometry, and biomechanical strength.
This is bone-mechanism support, not direct evidence for bodybuilding cycles in healthy adult users.
Viking Therapeutics completed a Phase II trial of VK5211 in hip fracture patients showing lean mass and stair-climbing power improvements.
Supports the rehab/lean-mass rationale in a clinical population, but this article does not provide dose, sample size, or publication detail sufficient to use it as a precise protocol anchor.
LGD-4033 parent compound and metabolites can be detected at very low levels, with the article citing around a 21-day urine detection window at supplement doses and 62 WADA adverse analytical findings in 2019.
This scopes legal/testing risk rather than clinical efficacy or safety.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.